233 related articles for article (PubMed ID: 1655149)
41. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
42. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
[TBL] [Abstract][Full Text] [Related]
43. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
44. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
45. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.
Griswold DE; Webb EF; Breton J; White JR; Marshall PJ; Torphy TJ
Inflammation; 1993 Jun; 17(3):333-44. PubMed ID: 7687237
[TBL] [Abstract][Full Text] [Related]
46. 8-(4-Chlorophenyl)thio-cyclic AMP is a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA).
Connolly BJ; Willits PB; Warrington BH; Murray KJ
Biochem Pharmacol; 1992 Dec; 44(12):2303-6. PubMed ID: 1335252
[TBL] [Abstract][Full Text] [Related]
47. High activity of low-Michaelis-Menten constant 3', 5'-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus.
Takeda S; Lin CT; Morgano PG; McIntyre SJ; Dousa TP
Endocrinology; 1991 Jul; 129(1):287-94. PubMed ID: 1647298
[TBL] [Abstract][Full Text] [Related]
48. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
49. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
50. Failure of nitric oxide donors to alter arrhythmias induced by acute myocardial ischaemia or reperfusion in anaesthetized rats.
Barnes CS; Coker SJ
Br J Pharmacol; 1995 Jan; 114(2):349-56. PubMed ID: 7881734
[TBL] [Abstract][Full Text] [Related]
51. Nitric oxide synthase and cGMP-mediated stimulation of renin secretion.
Sayago CM; Beierwaltes WH
Am J Physiol Regul Integr Comp Physiol; 2001 Oct; 281(4):R1146-51. PubMed ID: 11557622
[TBL] [Abstract][Full Text] [Related]
52. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.
Howell RE; Sickels BD; Woeppel SL
J Pharmacol Exp Ther; 1993 Feb; 264(2):609-15. PubMed ID: 8437112
[TBL] [Abstract][Full Text] [Related]
53. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.
Rabe KF; Tenor H; Dent G; Schudt C; Liebig S; Magnussen H
Am J Physiol; 1993 May; 264(5 Pt 1):L458-64. PubMed ID: 7684572
[TBL] [Abstract][Full Text] [Related]
54. Phosphodiesterase isoenzymes in human ureteral smooth muscle: identification, characterization, and functional effects of various phosphodiesterase inhibitors in vitro.
Stief CG; Taher A; Truss M; Becker AJ; Schulz-Knappe P; Meyer M; Uckert S; Forssmann WG; Jonas U
Urol Int; 1995; 55(4):183-9. PubMed ID: 8588263
[TBL] [Abstract][Full Text] [Related]
55. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
Barnette MS; Manning CD; Price WJ; Barone FC
J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
[TBL] [Abstract][Full Text] [Related]
56. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Weishaar RE; Cain MH; Bristol JA
J Med Chem; 1985 May; 28(5):537-45. PubMed ID: 2985781
[TBL] [Abstract][Full Text] [Related]
57. Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity.
Lidbury PS; Cirillo R; Vane JR
Br J Pharmacol; 1993 Sep; 110(1):275-80. PubMed ID: 8220889
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
59. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
60. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
Torphy TJ; Zhou HL; Cieslinski LB
J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
